Imatinib, Free base A bcr-abl tyrosine kinase inhibitor Product Overview Product Name: Imatinib, Free base Alternate Name/Synonyms: CGP-57148B, STI-571 Description: A free base form of Imatinib Mesylate (Cat. No. 1625-100, 1000). Peptide Sequence: N/A Appearance: Off-white solid Formulation: N/A CAS Number: 152459-95-5 Molecular Formula: C₂₉H₃₁N₇O Molecular Weight: 493.6 Purity: ≥99% by HPLC Solubility:DMSO (25 mg/ml) or EtOH (5 mg/ml) Storage Temp.: -20°C Shipping Conditions: gel pack Handling: Protect from air and light SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5 InChi: InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34) InChi Key: KTUFNOKKBVMGRW-UHFFFAOYSA-N PubChem CID: 5291 MDL Number: MFCD05662257 USAGE: For Research Use Only! Not For Use in Humans.
货号: 2141-1000 产品名称: Imatinib, Free base 品牌: Biovision 规格: 1 g 3周到货 生化实验
Imatinib, Free base A bcr-abl tyrosine kinase inhibitor Product Overview Product Name: Imatinib, Free base Alternate Name/Synonyms: CGP-57148B, STI-571 Description: A free base form of Imatinib Mesylate (Cat. No. 1625-100, 1000). Peptide Sequence: N/A Appearance: Off-white solid Formulation: N/A CAS Number: 152459-95-5 Molecular Formula: C₂₉H₃₁N₇O Molecular Weight: 493.6 Purity: ≥99% by HPLC Solubility:DMSO (25 mg/ml) or EtOH (5 mg/ml) Storage Temp.: -20°C Shipping Conditions: gel pack Handling: Protect from air and light SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5 InChi: InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34) InChi Key: KTUFNOKKBVMGRW-UHFFFAOYSA-N PubChem CID: 5291 MDL Number: MFCD05662257 USAGE: For Research Use Only! Not For Use in Humans.
货号: I-5508-1 g 产品名称: Imatinib, Methanesulfonate Salt 品牌: LC 规格: 1 g
I-5508 Imatinib, Methanesulfonate Salt, >99%[Imatinib Mesylate] [Gleevec] [Glivec] [CGP-57148B] [STI-571]M.W. 589.71 C29H31N7O•CH4SO3 [220127-57-1] M.I. 14: 4902 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; very poorly soluble in ethanol; soluble in water at 200 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A•Imatinib inhibits bcr-abl tyrosine kinase activity, upon which some types of tumor cells depend for growth. Imatinib acts by binding to the ATP binding site of bcr-abl and competitively inhibiting its tyrosine kinase activity. Imatinib is selective for bcr-abl, but it also targets several other kinases (c-kit and PDGF-R). Deininger, M. and Druker, B.J. “Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib.” Pharmacol. Rev. 55: 401-423 (2003).•Imatinib also stimulates the entry of the bcr-abl tyrosine kinase into the nucleus, where it cannot perform its anti-apoptopic functions. Vigneri, P. and Wang, J.Y. “Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.” Nat. Med. 7: 228-234 (2001).•Imatinib inhibits EOL-1 cell viability (IC50 = 0.5 nM), phosphorylation of a fusion protein (IC50 = 30 nM), and viability of BaF3 cells expressing Rhe-PDGFRα in the absence of IL-3 (IC50 = 0.17 nM). Griffin, J.H., et al. “Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.” Proc. Natl. Acad. Sci. USA 100: 7830-7835 (2003).•Inhibition of CSF-1R by imatinib is competitive with ATP, with a Ki value of 120 nM. Guo, J., et al. “Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.” Mol. Cancer Ther. 5: 1007-1013 (2006).•The IC50 values for imatinib inhibition of KBM5 and KBM7 cell growth were about 0.48 and 0.24 µM, respectively, while the IC50 values for imatinib in KBM5-STI571R1.0 and KBM7-STI571R1.0 cells were about 6.40 and 3.30 µM, respectively. (The data were from figure 2 but we found several errors in the figure. The correct data cannot be determined without further information). The calculated resistance indexes for imatinib were 13.3 for KBM5-STI571R1.0 cells and 13.8 for KBM7-STI571R1.0 cells. Golemovic, M., et al. “AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia.” Clin. Cancer Res. 11: 4941-4947 (2005).•Imatinib is the active ingredient in the drug sold under the trade name Gleevec® in USA or Glivec in Europe and Australia. This drug has been approved in at least one country for use in patients with gastrointestinal stromal tumors, chronic myelogenous leukemia and a number of other malignancies. NOTE: THE IMATINIB, METHANESULFONATE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GLEEVEC® OR GLIVEC, AND IS NOT FOR HUMAN USE.•Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.•This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.•Not available in some countries; not available to some institutions; not availabl
货号: I-5508-10 g 产品名称: Imatinib, Methanesulfonate Salt 品牌: LC 规格: 10 g
I-5508 Imatinib, Methanesulfonate Salt, >99%[Imatinib Mesylate] [Gleevec] [Glivec] [CGP-57148B] [STI-571]M.W. 589.71 C29H31N7O•CH4SO3 [220127-57-1] M.I. 14: 4902 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; very poorly soluble in ethanol; soluble in water at 200 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Imatinib inhibits bcr-abl tyrosine kinase activity, upon which some types of tumor cells depend for growth. Imatinib acts by binding to the ATP binding site of bcr-abl and competitively inhibiting its tyrosine kinase activity. Imatinib is selective for bcr-abl, but it also targets several other kinases (c-kit and PDGF-R). Deininger, M. and Druker, B.J. “Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib.” Pharmacol. Rev. 55: 401-423 (2003). •Imatinib also stimulates the entry of the bcr-abl tyrosine kinase into the nucleus, where it cannot perform its anti-apoptopic functions. Vigneri, P. and Wang, J.Y. “Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.” Nat. Med. 7: 228-234 (2001). •Imatinib inhibits EOL-1 cell viability (IC50 = 0.5 nM), phosphorylation of a fusion protein (IC50 = 30 nM), and viability of BaF3 cells expressing Rhe-PDGFRα in the absence of IL-3 (IC50 = 0.17 nM). Griffin, J.H., et al. “Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.” Proc. Natl. Acad. Sci. USA 100: 7830-7835 (2003). •Inhibition of CSF-1R by imatinib is competitive with ATP, with a Ki value of 120 nM. Guo, J., et al. “Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.” Mol. Cancer Ther. 5: 1007-1013 (2006). •The IC50 values for imatinib inhibition of KBM5 and KBM7 cell growth were about 0.48 and 0.24 µM, respectively, while the IC50 values for imatinib in KBM5-STI571R1.0 and KBM7-STI571R1.0 cells were about 6.40 and 3.30 µM, respectively. (The data were from figure 2 but we found several errors in the figure. The correct data cannot be determined without further information). The calculated resistance indexes for imatinib were 13.3 for KBM5-STI571R1.0 cells and 13.8 for KBM7-STI571R1.0 cells. Golemovic, M., et al. “AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia.” Clin. Cancer Res. 11: 4941-4947 (2005). •Imatinib is the active ingredient in the drug sold under the trade name Gleevec® in USA or Glivec in Europe and Australia. This drug has been approved in at least one country for use in patients with gastrointestinal stromal tumors, chronic myelogenous leukemia and a number of other malignancies. NOTE: THE IMATINIB, METHANESULFONATE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GLEEVEC® OR GLIVEC, AND IS NOT FOR HUMAN USE. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not availabl
货号: I-5508-2 g 产品名称: Imatinib, Methanesulfonate Salt 品牌: LC 规格: 2 g
I-5508 Imatinib, Methanesulfonate Salt, >99%[Imatinib Mesylate] [Gleevec] [Glivec] [CGP-57148B] [STI-571]M.W. 589.71 C29H31N7O•CH4SO3 [220127-57-1] M.I. 14: 4902 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; very poorly soluble in ethanol; soluble in water at 200 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Imatinib inhibits bcr-abl tyrosine kinase activity, upon which some types of tumor cells depend for growth. Imatinib acts by binding to the ATP binding site of bcr-abl and competitively inhibiting its tyrosine kinase activity. Imatinib is selective for bcr-abl, but it also targets several other kinases (c-kit and PDGF-R). Deininger, M. and Druker, B.J. “Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib.” Pharmacol. Rev. 55: 401-423 (2003). •Imatinib also stimulates the entry of the bcr-abl tyrosine kinase into the nucleus, where it cannot perform its anti-apoptopic functions. Vigneri, P. and Wang, J.Y. “Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.” Nat. Med. 7: 228-234 (2001). •Imatinib inhibits EOL-1 cell viability (IC50 = 0.5 nM), phosphorylation of a fusion protein (IC50 = 30 nM), and viability of BaF3 cells expressing Rhe-PDGFRα in the absence of IL-3 (IC50 = 0.17 nM). Griffin, J.H., et al. “Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.” Proc. Natl. Acad. Sci. USA 100: 7830-7835 (2003). •Inhibition of CSF-1R by imatinib is competitive with ATP, with a Ki value of 120 nM. Guo, J., et al. “Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.” Mol. Cancer Ther. 5: 1007-1013 (2006). •The IC50 values for imatinib inhibition of KBM5 and KBM7 cell growth were about 0.48 and 0.24 µM, respectively, while the IC50 values for imatinib in KBM5-STI571R1.0 and KBM7-STI571R1.0 cells were about 6.40 and 3.30 µM, respectively. (The data were from figure 2 but we found several errors in the figure. The correct data cannot be determined without further information). The calculated resistance indexes for imatinib were 13.3 for KBM5-STI571R1.0 cells and 13.8 for KBM7-STI571R1.0 cells. Golemovic, M., et al. “AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia.” Clin. Cancer Res. 11: 4941-4947 (2005). •Imatinib is the active ingredient in the drug sold under the trade name Gleevec® in USA or Glivec in Europe and Australia. This drug has been approved in at least one country for use in patients with gastrointestinal stromal tumors, chronic myelogenous leukemia and a number of other malignancies. NOTE: THE IMATINIB, METHANESULFONATE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GLEEVEC® OR GLIVEC, AND IS NOT FOR HUMAN USE. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not availabl
货号: I-5508-25 g 产品名称: Imatinib, Methanesulfonate Salt 品牌: LC 规格: 25 g
I-5508 Imatinib, Methanesulfonate Salt, >99%[Imatinib Mesylate] [Gleevec] [Glivec] [CGP-57148B] [STI-571]M.W. 589.71 C29H31N7O•CH4SO3 [220127-57-1] M.I. 14: 4902 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; very poorly soluble in ethanol; soluble in water at 200 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Imatinib inhibits bcr-abl tyrosine kinase activity, upon which some types of tumor cells depend for growth. Imatinib acts by binding to the ATP binding site of bcr-abl and competitively inhibiting its tyrosine kinase activity. Imatinib is selective for bcr-abl, but it also targets several other kinases (c-kit and PDGF-R). Deininger, M. and Druker, B.J. “Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib.” Pharmacol. Rev. 55: 401-423 (2003). •Imatinib also stimulates the entry of the bcr-abl tyrosine kinase into the nucleus, where it cannot perform its anti-apoptopic functions. Vigneri, P. and Wang, J.Y. “Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.” Nat. Med. 7: 228-234 (2001). •Imatinib inhibits EOL-1 cell viability (IC50 = 0.5 nM), phosphorylation of a fusion protein (IC50 = 30 nM), and viability of BaF3 cells expressing Rhe-PDGFRα in the absence of IL-3 (IC50 = 0.17 nM). Griffin, J.H., et al. “Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.” Proc. Natl. Acad. Sci. USA 100: 7830-7835 (2003). •Inhibition of CSF-1R by imatinib is competitive with ATP, with a Ki value of 120 nM. Guo, J., et al. “Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.” Mol. Cancer Ther. 5: 1007-1013 (2006). •The IC50 values for imatinib inhibition of KBM5 and KBM7 cell growth were about 0.48 and 0.24 µM, respectively, while the IC50 values for imatinib in KBM5-STI571R1.0 and KBM7-STI571R1.0 cells were about 6.40 and 3.30 µM, respectively. (The data were from figure 2 but we found several errors in the figure. The correct data cannot be determined without further information). The calculated resistance indexes for imatinib were 13.3 for KBM5-STI571R1.0 cells and 13.8 for KBM7-STI571R1.0 cells. Golemovic, M., et al. “AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia.” Clin. Cancer Res. 11: 4941-4947 (2005). •Imatinib is the active ingredient in the drug sold under the trade name Gleevec® in USA or Glivec in Europe and Australia. This drug has been approved in at least one country for use in patients with gastrointestinal stromal tumors, chronic myelogenous leukemia and a number of other malignancies. NOTE: THE IMATINIB, METHANESULFONATE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GLEEVEC® OR GLIVEC, AND IS NOT FOR HUMAN USE. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not availabl
货号: I-5508-5 g 产品名称: Imatinib, Methanesulfonate Salt 品牌: LC 规格: 5 g
I-5508 Imatinib, Methanesulfonate Salt, >99%[Imatinib Mesylate] [Gleevec] [Glivec] [CGP-57148B] [STI-571]M.W. 589.71 C29H31N7O•CH4SO3 [220127-57-1] M.I. 14: 4902 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; very poorly soluble in ethanol; soluble in water at 200 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Imatinib inhibits bcr-abl tyrosine kinase activity, upon which some types of tumor cells depend for growth. Imatinib acts by binding to the ATP binding site of bcr-abl and competitively inhibiting its tyrosine kinase activity. Imatinib is selective for bcr-abl, but it also targets several other kinases (c-kit and PDGF-R). Deininger, M. and Druker, B.J. “Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib.” Pharmacol. Rev. 55: 401-423 (2003). •Imatinib also stimulates the entry of the bcr-abl tyrosine kinase into the nucleus, where it cannot perform its anti-apoptopic functions. Vigneri, P. and Wang, J.Y. “Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.” Nat. Med. 7: 228-234 (2001). •Imatinib inhibits EOL-1 cell viability (IC50 = 0.5 nM), phosphorylation of a fusion protein (IC50 = 30 nM), and viability of BaF3 cells expressing Rhe-PDGFRα in the absence of IL-3 (IC50 = 0.17 nM). Griffin, J.H., et al. “Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.” Proc. Natl. Acad. Sci. USA 100: 7830-7835 (2003). •Inhibition of CSF-1R by imatinib is competitive with ATP, with a Ki value of 120 nM. Guo, J., et al. “Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.” Mol. Cancer Ther. 5: 1007-1013 (2006). •The IC50 values for imatinib inhibition of KBM5 and KBM7 cell growth were about 0.48 and 0.24 µM, respectively, while the IC50 values for imatinib in KBM5-STI571R1.0 and KBM7-STI571R1.0 cells were about 6.40 and 3.30 µM, respectively. (The data were from figure 2 but we found several errors in the figure. The correct data cannot be determined without further information). The calculated resistance indexes for imatinib were 13.3 for KBM5-STI571R1.0 cells and 13.8 for KBM7-STI571R1.0 cells. Golemovic, M., et al. “AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia.” Clin. Cancer Res. 11: 4941-4947 (2005). •Imatinib is the active ingredient in the drug sold under the trade name Gleevec® in USA or Glivec in Europe and Australia. This drug has been approved in at least one country for use in patients with gastrointestinal stromal tumors, chronic myelogenous leukemia and a number of other malignancies. NOTE: THE IMATINIB, METHANESULFONATE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GLEEVEC® OR GLIVEC, AND IS NOT FOR HUMAN USE. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not availabl
I-5508 Imatinib, Methanesulfonate Salt, >99%[Imatinib Mesylate] [Gleevec] [Glivec] [CGP-57148B] [STI-571]M.W. 589.71 C29H31N7O•CH4SO3 [220127-57-1] M.I. 14: 4902 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; very poorly soluble in ethanol; soluble in water at 200 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •Imatinib inhibits bcr-abl tyrosine kinase activity, upon which some types of tumor cells depend for growth. Imatinib acts by binding to the ATP binding site of bcr-abl and competitively inhibiting its tyrosine kinase activity. Imatinib is selective for bcr-abl, but it also targets several other kinases (c-kit and PDGF-R). Deininger, M. and Druker, B.J. “Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib.” Pharmacol. Rev. 55: 401-423 (2003). •Imatinib also stimulates the entry of the bcr-abl tyrosine kinase into the nucleus, where it cannot perform its anti-apoptopic functions. Vigneri, P. and Wang, J.Y. “Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.” Nat. Med. 7: 228-234 (2001). •Imatinib inhibits EOL-1 cell viability (IC50 = 0.5 nM), phosphorylation of a fusion protein (IC50 = 30 nM), and viability of BaF3 cells expressing Rhe-PDGFRα in the absence of IL-3 (IC50 = 0.17 nM). Griffin, J.H., et al. “Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.” Proc. Natl. Acad. Sci. USA 100: 7830-7835 (2003). •Inhibition of CSF-1R by imatinib is competitive with ATP, with a Ki value of 120 nM. Guo, J., et al. “Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.” Mol. Cancer Ther. 5: 1007-1013 (2006). •The IC50 values for imatinib inhibition of KBM5 and KBM7 cell growth were about 0.48 and 0.24 µM, respectively, while the IC50 values for imatinib in KBM5-STI571R1.0 and KBM7-STI571R1.0 cells were about 6.40 and 3.30 µM, respectively. (The data were from figure 2 but we found several errors in the figure. The correct data cannot be determined without further information). The calculated resistance indexes for imatinib were 13.3 for KBM5-STI571R1.0 cells and 13.8 for KBM7-STI571R1.0 cells. Golemovic, M., et al. “AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia.” Clin. Cancer Res. 11: 4941-4947 (2005). •Imatinib is the active ingredient in the drug sold under the trade name Gleevec® in USA or Glivec in Europe and Australia. This drug has been approved in at least one country for use in patients with gastrointestinal stromal tumors, chronic myelogenous leukemia and a number of other malignancies. NOTE: THE IMATINIB, METHANESULFONATE SALT RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GLEEVEC® OR GLIVEC, AND IS NOT FOR HUMAN USE. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not availabl
货号: I-5577-1 g 产品名称: Imatinib, Free Base 品牌: LC 规格: 1 g
I-5577 Imatinib, Free Base, >99%Synonyms: [CGP-57148B] [STI-571] Related Terms: [Glamox] [Gleevec] [Glivec] M.W. 493.60 C29H31N7O [152459-95-5] M.I. 14: 4902 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 25 mg/mL with slight warming; soluble in ethanol at 5 mg/mL with slight warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •This is the free base form of imatinib; please see the other form of this product, Imatinib, Methanesulfonate Salt, Cat. No. I-5508, for further technical information. The methanesulfonate salt form of imatinib is used for some or all imatinib formulation for use in humans. •Imatinib is the active ingredient in the drug product sold under the trade name Gleevec® and the other trade names listed above under “Related Terms”. This drug has been approved in at least one country for use in patients with gastrointestinal stromal tumors, chronic myelogenous leukemia and a number of other malignancies. NOTE: THE IMATINIB, FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GLEEVEC® NOR ANY OTHER DRUG PRODUCT SPECIFIED BY THE TRADE NAMES LISTED ABOVE UNDER “RELATED TERMS”, AND IS NOT FOR HUMAN USE. •NOTE: the trade names listed above under “Related Terms” are for imatinib-containing drug products and may apply variously to formulations of one or another form of imatinib, such as the free base, mesylate salt, or other forms. •This imatinib product is the free base, whose CAS number is given above. The CAS number of the methanesulfonate salt is 220127-57-1. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not available for some uses.
货号: I-5577-10 g 产品名称: Imatinib, Free Base 品牌: LC 规格: 10 g
I-5577 Imatinib, Free Base, >99%Synonyms: [CGP-57148B] [STI-571] Related Terms: [Glamox] [Gleevec] [Glivec] M.W. 493.60 C29H31N7O [152459-95-5] M.I. 14: 4902 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 25 mg/mL with slight warming; soluble in ethanol at 5 mg/mL with slight warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •This is the free base form of imatinib; please see the other form of this product, Imatinib, Methanesulfonate Salt, Cat. No. I-5508, for further technical information. The methanesulfonate salt form of imatinib is used for some or all imatinib formulation for use in humans. •Imatinib is the active ingredient in the drug product sold under the trade name Gleevec® and the other trade names listed above under “Related Terms”. This drug has been approved in at least one country for use in patients with gastrointestinal stromal tumors, chronic myelogenous leukemia and a number of other malignancies. NOTE: THE IMATINIB, FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GLEEVEC® NOR ANY OTHER DRUG PRODUCT SPECIFIED BY THE TRADE NAMES LISTED ABOVE UNDER “RELATED TERMS”, AND IS NOT FOR HUMAN USE. •NOTE: the trade names listed above under “Related Terms” are for imatinib-containing drug products and may apply variously to formulations of one or another form of imatinib, such as the free base, mesylate salt, or other forms. •This imatinib product is the free base, whose CAS number is given above. The CAS number of the methanesulfonate salt is 220127-57-1. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not available for some uses.
货号: I-5577-2 g 产品名称: Imatinib, Free Base 品牌: LC 规格: 2 g
I-5577 Imatinib, Free Base, >99%Synonyms: [CGP-57148B] [STI-571] Related Terms: [Glamox] [Gleevec] [Glivec] M.W. 493.60 C29H31N7O [152459-95-5] M.I. 14: 4902 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 25 mg/mL with slight warming; soluble in ethanol at 5 mg/mL with slight warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •This is the free base form of imatinib; please see the other form of this product, Imatinib, Methanesulfonate Salt, Cat. No. I-5508, for further technical information. The methanesulfonate salt form of imatinib is used for some or all imatinib formulation for use in humans. •Imatinib is the active ingredient in the drug product sold under the trade name Gleevec® and the other trade names listed above under “Related Terms”. This drug has been approved in at least one country for use in patients with gastrointestinal stromal tumors, chronic myelogenous leukemia and a number of other malignancies. NOTE: THE IMATINIB, FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GLEEVEC® NOR ANY OTHER DRUG PRODUCT SPECIFIED BY THE TRADE NAMES LISTED ABOVE UNDER “RELATED TERMS”, AND IS NOT FOR HUMAN USE. •NOTE: the trade names listed above under “Related Terms” are for imatinib-containing drug products and may apply variously to formulations of one or another form of imatinib, such as the free base, mesylate salt, or other forms. •This imatinib product is the free base, whose CAS number is given above. The CAS number of the methanesulfonate salt is 220127-57-1. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not available for some uses.
货号: I-5577-25 g 产品名称: Imatinib, Free Base 品牌: LC 规格: 25 g
I-5577 Imatinib, Free Base, >99%Synonyms: [CGP-57148B] [STI-571] Related Terms: [Glamox] [Gleevec] [Glivec] M.W. 493.60 C29H31N7O [152459-95-5] M.I. 14: 4902 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 25 mg/mL with slight warming; soluble in ethanol at 5 mg/mL with slight warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •This is the free base form of imatinib; please see the other form of this product, Imatinib, Methanesulfonate Salt, Cat. No. I-5508, for further technical information. The methanesulfonate salt form of imatinib is used for some or all imatinib formulation for use in humans. •Imatinib is the active ingredient in the drug product sold under the trade name Gleevec® and the other trade names listed above under “Related Terms”. This drug has been approved in at least one country for use in patients with gastrointestinal stromal tumors, chronic myelogenous leukemia and a number of other malignancies. NOTE: THE IMATINIB, FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GLEEVEC® NOR ANY OTHER DRUG PRODUCT SPECIFIED BY THE TRADE NAMES LISTED ABOVE UNDER “RELATED TERMS”, AND IS NOT FOR HUMAN USE. •NOTE: the trade names listed above under “Related Terms” are for imatinib-containing drug products and may apply variously to formulations of one or another form of imatinib, such as the free base, mesylate salt, or other forms. •This imatinib product is the free base, whose CAS number is given above. The CAS number of the methanesulfonate salt is 220127-57-1. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not available for some uses.
货号: I-5577-5 g 产品名称: Imatinib, Free Base 品牌: LC 规格: 5 g
I-5577 Imatinib, Free Base, >99%Synonyms: [CGP-57148B] [STI-571] Related Terms: [Glamox] [Gleevec] [Glivec] M.W. 493.60 C29H31N7O [152459-95-5] M.I. 14: 4902 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 25 mg/mL with slight warming; soluble in ethanol at 5 mg/mL with slight warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •This is the free base form of imatinib; please see the other form of this product, Imatinib, Methanesulfonate Salt, Cat. No. I-5508, for further technical information. The methanesulfonate salt form of imatinib is used for some or all imatinib formulation for use in humans. •Imatinib is the active ingredient in the drug product sold under the trade name Gleevec® and the other trade names listed above under “Related Terms”. This drug has been approved in at least one country for use in patients with gastrointestinal stromal tumors, chronic myelogenous leukemia and a number of other malignancies. NOTE: THE IMATINIB, FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GLEEVEC® NOR ANY OTHER DRUG PRODUCT SPECIFIED BY THE TRADE NAMES LISTED ABOVE UNDER “RELATED TERMS”, AND IS NOT FOR HUMAN USE. •NOTE: the trade names listed above under “Related Terms” are for imatinib-containing drug products and may apply variously to formulations of one or another form of imatinib, such as the free base, mesylate salt, or other forms. •This imatinib product is the free base, whose CAS number is given above. The CAS number of the methanesulfonate salt is 220127-57-1. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not available for some uses.
I-5577 Imatinib, Free Base, >99%Synonyms: [CGP-57148B] [STI-571] Related Terms: [Glamox] [Gleevec] [Glivec] M.W. 493.60 C29H31N7O [152459-95-5] M.I. 14: 4902 Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 25 mg/mL with slight warming; soluble in ethanol at 5 mg/mL with slight warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 5-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A •This is the free base form of imatinib; please see the other form of this product, Imatinib, Methanesulfonate Salt, Cat. No. I-5508, for further technical information. The methanesulfonate salt form of imatinib is used for some or all imatinib formulation for use in humans. •Imatinib is the active ingredient in the drug product sold under the trade name Gleevec® and the other trade names listed above under “Related Terms”. This drug has been approved in at least one country for use in patients with gastrointestinal stromal tumors, chronic myelogenous leukemia and a number of other malignancies. NOTE: THE IMATINIB, FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT GLEEVEC® NOR ANY OTHER DRUG PRODUCT SPECIFIED BY THE TRADE NAMES LISTED ABOVE UNDER “RELATED TERMS”, AND IS NOT FOR HUMAN USE. •NOTE: the trade names listed above under “Related Terms” are for imatinib-containing drug products and may apply variously to formulations of one or another form of imatinib, such as the free base, mesylate salt, or other forms. •This imatinib product is the free base, whose CAS number is given above. The CAS number of the methanesulfonate salt is 220127-57-1. •Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use. •This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries. •Not available in some countries; not available to some institutions; not available for some uses.